Jci_page_head_homepage_01 Jci_page_head_homepage_02
Marion C. Lanteri, Katie M. O’Brien, Whitney E. Purtha, Mark J. Cameron, Jennifer M. Lund, Rachel E. Owen, John W. Heitman, Brian Custer, Dale F. Hirschkorn, Leslie H. Tobler, Nancy Kiely, Harry E. Prince, Lishomwa C. Ndhlovu, Douglas F. Nixon, Hany T. Kamel, David J. Kelvin, Michael P. Busch, Alexander Y. Rudensky, Michael S. Diamond, Philip J. Norris
Published in Volume 119, Issue 11
J Clin Invest. 2009; 119(11):3266–3277 doi:10.1172/JCI39387
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 2
Suppressive capacity of Tregs.

(A) Comparison of CD25, CD127, and CD152 expression within CD4+ T cell fractions before magnetic bead separation (left panels) and after separation within Treg-depleted PBMCs (middle panels) and purified Tregs (right panels) from a normal human control. (B) CD25-depleted CD4+ T cells from a normal control and a representative WNV+ donor were stained with CFSE (CFSE+, right peak and middle population). After 4 days of incubation alone, with anti-CD3/CD28, or with anti-CD3/CD28 plus Tregs (CFSE, left peak), proliferation was analyzed after staining for CD4 and propidium iodide. Tregs were not stained and appear at the far left of the plot. Dot plots are shown for 1 representative WNV donor. (C) Bar diagrams are representative of 3 WNV and 3 WNV+ donors, with samples collected 30 days after index donation for the WNV+ donors. Treg suppression of anti-CD3/CD28–induced proliferation at 4 days is shown at varied effector to Treg ratios, averaging experiments from 3 WNV and WNV+ donors (error bars represent SEM).